The effect of remimazolam combined with alfentanil in gastrointestinal endoscopic procedures sedation: a prospective study

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000041551

Enrollment

Unknown

Registered

2020-12-28

Start date

2021-01-15

Completion date

Unknown

Last updated

2021-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative central nervous system dysfunction

Interventions

1:Intravenous remazolam

1:Intravenous alfentanil

Eligibility

Sex/Gender

All

Age

16 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Patients with ASA classification I-II undergoing digestive endoscopy and need to be sedated; 2. Aged >= 16 years; 3. Fasting for >= 6 hours before the examination, and no drinking for >= 2 hours.

Exclusion criteria

Exclusion criteria: 1. Patients with a high risk of satiety reflux aspiration; 2. Patients are allergic to benzodiazepines; 3. Patients are allergic to opioids; 4. Patients have taken sedatives in the past; 5. Patients cannot cooperate with communication. 6. Emergency patients.

Design outcomes

Primary

Measure	Time frame
rate of redation success;	—

Secondary

Measure	Time frame
Postoperative adverse reactions;	—

Countries

China

Contacts

Public ContactYunqi Lyu

The First Affiliated Hospital of Zhengzhou University

yymchelong@126.com+86 13939019005

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026